The estimated Net Worth of John C Jacobs is at least 4.04 百万$ dollars as of 23 January 2024. Mr Jacobs owns over 83,197 units of Harmony Biosciences stock worth over 3,101,584$ and over the last 3 years he sold HRMY stock worth over 0$. In addition, he makes 933,938$ as Pres、 CEO & Director at Harmony Biosciences.
Mr has made over 10 trades of the Harmony Biosciences stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 83,197 units of HRMY stock worth 3,101,584$ on 23 January 2024.
The largest trade he's ever made was exercising 83,197 units of Harmony Biosciences stock on 23 January 2024 worth over 3,101,584$. On average, Mr trades about 23,600 units every 72 days since 2021. As of 23 January 2024 he still owns at least 83,197 units of Harmony Biosciences stock.
You can see the complete history of Mr Jacobs stock trades at the bottom of the page.
John Charles Jacobs M.B.A. is the Pres, CEO & Director at Harmony Biosciences.
As the Pres、 CEO & Director of Harmony Biosciences, the total compensation of Mr A at Harmony Biosciences is 933,938$. There are no executives at Harmony Biosciences getting paid more.
Mr A is 54, he's been the Pres、 CEO & Director of Harmony Biosciences since . There are 1 older and 4 younger executives at Harmony Biosciences. The oldest executive at Harmony Biosciences Holdings, Inc. is Dr. Jeffrey M. Dayno M.D., 64, who is the Chief Medical Officer.
John's mailing address filed with the SEC is C/O NOVAVAX, INC., 700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD, 20878.
Over the last 4 years, insiders at Harmony Biosciences have traded over 224,163,932$ worth of Harmony Biosciences stock and bought 514,681 units worth 12,537,009$ . The most active insiders traders include Holdings A/S Novo、Andreas Wicki、Antonio J. Gracias. On average, Harmony Biosciences executives and independent directors trade stock every 19 days with the average trade being worth of 2,907,691$. The most recent stock trade was executed by Sandip Kapadia on 29 March 2024, trading 15,000 units of HRMY stock currently worth 559,200$.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Harmony Biosciences executives and other stock owners filed with the SEC include: